Cargando…

Systematic Review and Patient‐Level Meta‐Analysis of SARS‐CoV‐2 Viral Dynamics to Model Response to Antiviral Therapies

Severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2) viral loads change rapidly following symptom onset, so to assess antivirals it is important to understand the natural history and patient factors influencing this. We undertook an individual patient‐level meta‐analysis of SARS‐CoV‐2 viral...

Descripción completa

Detalles Bibliográficos
Autores principales: Gastine, Silke, Pang, Juanita, Boshier, Florencia A.T., Carter, Simon J., Lonsdale, Dagan O., Cortina‐Borja, Mario, Hung, Ivan F.N., Breuer, Judy, Kloprogge, Frank, Standing, Joseph F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8014833/
https://www.ncbi.nlm.nih.gov/pubmed/33641159
http://dx.doi.org/10.1002/cpt.2223
_version_ 1783673574948601856
author Gastine, Silke
Pang, Juanita
Boshier, Florencia A.T.
Carter, Simon J.
Lonsdale, Dagan O.
Cortina‐Borja, Mario
Hung, Ivan F.N.
Breuer, Judy
Kloprogge, Frank
Standing, Joseph F.
author_facet Gastine, Silke
Pang, Juanita
Boshier, Florencia A.T.
Carter, Simon J.
Lonsdale, Dagan O.
Cortina‐Borja, Mario
Hung, Ivan F.N.
Breuer, Judy
Kloprogge, Frank
Standing, Joseph F.
author_sort Gastine, Silke
collection PubMed
description Severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2) viral loads change rapidly following symptom onset, so to assess antivirals it is important to understand the natural history and patient factors influencing this. We undertook an individual patient‐level meta‐analysis of SARS‐CoV‐2 viral dynamics in humans to describe viral dynamics and estimate the effects of antivirals used to date. This systematic review identified case reports, case series, and clinical trial data from publications between January 1, 2020, and May 31, 2020, following Preferred Reporting Items for Systematic Reviews and Meta‐Analyses guidelines. A multivariable Cox proportional hazards (Cox‐PH) regression model of time to viral clearance was fitted to respiratory and stool samples. A simplified four parameter nonlinear mixed‐effects (NLME) model was fitted to viral load trajectories in all sampling sites and covariate modeling of respiratory viral dynamics was performed to quantify time‐dependent drug effects. Patient‐level data from 645 individuals (age 1 month to 100 years) with 6,316 viral loads were extracted. Model‐based simulations of viral load trajectories in samples from the upper and lower respiratory tract, stool, blood, urine, ocular secretions, and breast milk were generated. Cox‐PH modeling showed longer time to viral clearance in older patients, men, and those with more severe disease. Remdesivir was associated with faster viral clearance (adjusted hazard ratio (AHR) = 9.19, P < 0.001), as well as interferon, particularly when combined with ribavirin (AHR = 2.2, P = 0.015; AHR = 6.04, P = 0.006). Combination therapy should be further investigated. A viral dynamic dataset and NLME model for designing and analyzing antiviral trials has been established.
format Online
Article
Text
id pubmed-8014833
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-80148332021-04-01 Systematic Review and Patient‐Level Meta‐Analysis of SARS‐CoV‐2 Viral Dynamics to Model Response to Antiviral Therapies Gastine, Silke Pang, Juanita Boshier, Florencia A.T. Carter, Simon J. Lonsdale, Dagan O. Cortina‐Borja, Mario Hung, Ivan F.N. Breuer, Judy Kloprogge, Frank Standing, Joseph F. Clin Pharmacol Ther Reviews Severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2) viral loads change rapidly following symptom onset, so to assess antivirals it is important to understand the natural history and patient factors influencing this. We undertook an individual patient‐level meta‐analysis of SARS‐CoV‐2 viral dynamics in humans to describe viral dynamics and estimate the effects of antivirals used to date. This systematic review identified case reports, case series, and clinical trial data from publications between January 1, 2020, and May 31, 2020, following Preferred Reporting Items for Systematic Reviews and Meta‐Analyses guidelines. A multivariable Cox proportional hazards (Cox‐PH) regression model of time to viral clearance was fitted to respiratory and stool samples. A simplified four parameter nonlinear mixed‐effects (NLME) model was fitted to viral load trajectories in all sampling sites and covariate modeling of respiratory viral dynamics was performed to quantify time‐dependent drug effects. Patient‐level data from 645 individuals (age 1 month to 100 years) with 6,316 viral loads were extracted. Model‐based simulations of viral load trajectories in samples from the upper and lower respiratory tract, stool, blood, urine, ocular secretions, and breast milk were generated. Cox‐PH modeling showed longer time to viral clearance in older patients, men, and those with more severe disease. Remdesivir was associated with faster viral clearance (adjusted hazard ratio (AHR) = 9.19, P < 0.001), as well as interferon, particularly when combined with ribavirin (AHR = 2.2, P = 0.015; AHR = 6.04, P = 0.006). Combination therapy should be further investigated. A viral dynamic dataset and NLME model for designing and analyzing antiviral trials has been established. John Wiley and Sons Inc. 2021-05-01 2021-08 /pmc/articles/PMC8014833/ /pubmed/33641159 http://dx.doi.org/10.1002/cpt.2223 Text en © 2021 The Authors. Clinical Pharmacology & Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Reviews
Gastine, Silke
Pang, Juanita
Boshier, Florencia A.T.
Carter, Simon J.
Lonsdale, Dagan O.
Cortina‐Borja, Mario
Hung, Ivan F.N.
Breuer, Judy
Kloprogge, Frank
Standing, Joseph F.
Systematic Review and Patient‐Level Meta‐Analysis of SARS‐CoV‐2 Viral Dynamics to Model Response to Antiviral Therapies
title Systematic Review and Patient‐Level Meta‐Analysis of SARS‐CoV‐2 Viral Dynamics to Model Response to Antiviral Therapies
title_full Systematic Review and Patient‐Level Meta‐Analysis of SARS‐CoV‐2 Viral Dynamics to Model Response to Antiviral Therapies
title_fullStr Systematic Review and Patient‐Level Meta‐Analysis of SARS‐CoV‐2 Viral Dynamics to Model Response to Antiviral Therapies
title_full_unstemmed Systematic Review and Patient‐Level Meta‐Analysis of SARS‐CoV‐2 Viral Dynamics to Model Response to Antiviral Therapies
title_short Systematic Review and Patient‐Level Meta‐Analysis of SARS‐CoV‐2 Viral Dynamics to Model Response to Antiviral Therapies
title_sort systematic review and patient‐level meta‐analysis of sars‐cov‐2 viral dynamics to model response to antiviral therapies
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8014833/
https://www.ncbi.nlm.nih.gov/pubmed/33641159
http://dx.doi.org/10.1002/cpt.2223
work_keys_str_mv AT gastinesilke systematicreviewandpatientlevelmetaanalysisofsarscov2viraldynamicstomodelresponsetoantiviraltherapies
AT pangjuanita systematicreviewandpatientlevelmetaanalysisofsarscov2viraldynamicstomodelresponsetoantiviraltherapies
AT boshierflorenciaat systematicreviewandpatientlevelmetaanalysisofsarscov2viraldynamicstomodelresponsetoantiviraltherapies
AT cartersimonj systematicreviewandpatientlevelmetaanalysisofsarscov2viraldynamicstomodelresponsetoantiviraltherapies
AT lonsdaledagano systematicreviewandpatientlevelmetaanalysisofsarscov2viraldynamicstomodelresponsetoantiviraltherapies
AT cortinaborjamario systematicreviewandpatientlevelmetaanalysisofsarscov2viraldynamicstomodelresponsetoantiviraltherapies
AT hungivanfn systematicreviewandpatientlevelmetaanalysisofsarscov2viraldynamicstomodelresponsetoantiviraltherapies
AT breuerjudy systematicreviewandpatientlevelmetaanalysisofsarscov2viraldynamicstomodelresponsetoantiviraltherapies
AT kloproggefrank systematicreviewandpatientlevelmetaanalysisofsarscov2viraldynamicstomodelresponsetoantiviraltherapies
AT standingjosephf systematicreviewandpatientlevelmetaanalysisofsarscov2viraldynamicstomodelresponsetoantiviraltherapies